These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 32745279

  • 1. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
    Van der Linden N, Van Olst S, Nekeman S, Uyl-de Groot CA.
    Diabet Med; 2021 Apr; 38(4):e14371. PubMed ID: 32745279
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
    BMC Health Serv Res; 2015 Nov 05; 15():496. PubMed ID: 26541516
    [Abstract] [Full Text] [Related]

  • 4. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
    Diabet Med; 2015 Jul 05; 32(7):890-8. PubMed ID: 25817050
    [Abstract] [Full Text] [Related]

  • 5. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM, Kim JJ, Kim HJ, Sohn HS.
    Cardiovasc Diabetol; 2020 Jun 22; 19(1):95. PubMed ID: 32571319
    [Abstract] [Full Text] [Related]

  • 6. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
    Elsisi GH, Anwar MM, Khattab M, Elebrashy I, Wafa A, Elhadad H, Awad M, Carapinha JL.
    J Med Econ; 2020 Aug 22; 23(8):908-914. PubMed ID: 32364032
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U, Ekman M, Granström O, Bergenheim K, McEwan P.
    Prim Care Diabetes; 2015 Feb 22; 9(1):39-47. PubMed ID: 24840612
    [Abstract] [Full Text] [Related]

  • 8. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A, Rastogi M, Dhankhar P, Bell KF.
    J Med Econ; 2018 May 22; 21(5):497-509. PubMed ID: 29376760
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Cai X, Shi L, Yang W, Gu S, Chen Y, Nie L, Ji L.
    J Med Econ; 2019 Apr 22; 22(4):336-343. PubMed ID: 30663458
    [Abstract] [Full Text] [Related]

  • 10. [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].
    Abad Paniagua EJ, Casado Escribano P, Fernández Rodriguez JM, Morales Escobar FJ, Betegón Nicolás L, Sánchez-Covisa J, Brosa M.
    Aten Primaria; 2015 Oct 22; 47(8):505-13. PubMed ID: 25555492
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L.
    Curr Med Res Opin; 2017 Feb 22; 33(2):359-369. PubMed ID: 27817216
    [Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
    van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M.
    Clin Drug Investig; 2014 Feb 22; 34(2):135-46. PubMed ID: 24243529
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
    Lasalvia P, Gil-Rojas Y, García Á.
    Expert Rev Pharmacoecon Outcomes Res; 2022 Sep 22; 22(6):955-964. PubMed ID: 35259045
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R.
    BMC Health Serv Res; 2018 Feb 01; 18(1):78. PubMed ID: 29391064
    [Abstract] [Full Text] [Related]

  • 15. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.
    Asche CV, Hippler SE, Eurich DT.
    Pharmacoeconomics; 2014 Jan 01; 32(1):15-27. PubMed ID: 24357160
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
    Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M.
    Prim Care Diabetes; 2012 Jul 01; 6(2):127-36. PubMed ID: 22001114
    [Abstract] [Full Text] [Related]

  • 17. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ, Lee DH, Jeon HJ, Oh TK.
    Diabetes Res Clin Pract; 2019 May 01; 151():65-73. PubMed ID: 30954510
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
    Pawaskar M, Bilir SP, Kowal S, Gonzalez C, Rajpathak S, Davies G.
    Am J Manag Care; 2019 May 01; 25(5):231-238. PubMed ID: 31120717
    [Abstract] [Full Text] [Related]

  • 19. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 01; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
    Liao CT, Yang CT, Toh HS, Chang WT, Chang HY, Kuo FH, Lee MC, Hua YM, Tang HJ, Strong C, Ou HT.
    Cardiovasc Diabetol; 2021 Oct 09; 20(1):204. PubMed ID: 34627231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.